Skip to content

Hospital Readmission After HIPr Fracture. Impact of a Territorial Fracture Liason Service

Hospital Readmission After HIPr Fracture. Impact of a Territorial Fracture Liason Service

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05266755
Acronym
FLSSantPau
Enrollment
120
Registered
2022-03-04
Start date
2022-03-15
Completion date
2023-04-01
Last updated
2022-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fractures

Brief summary

The International Osteoporosis Foundation (IOF) and the American Society for Bone Research and Mineral Metabolism recommend the creation and implementation of fracture coordination services (FLS) as the most efficient way to address the problem. FLS has emerged as a new clinical approach that uses coordinated, multidisciplinary care to improve post-fracture outcomes and reduce recurrent fractures. It is a multidisciplinary and protocolized care model that must guarantee: 1. Identify fragility fractures and people at risk for a fracture 2. Fracture risk assessment 3. Indication for treatment or referral 4. Improvement in therapeutic compliance 5. Reduce the risk of falls It is known that patients who have undergone a FLS model (vs no FLS), have lower mortality, lower risk of fracture, with a reduction of 35% and 56%, respectively, during two years of follow-up. One of the most important objectives of the FLS is the proper recognition and treatment of osteoporosis (OP) in patients with fragility fractures. A major problem is the lack of adherence to treatment for OP, and inclusion in an FLS program increases the prescription of bisphosphonates from 17.9% to 76%. In addition, a specific follow-up program means that 73% of patients followed by FLS continue to undergo anti-resorptive treatment after 2 years of having suffered a femur fracture.

Detailed description

Hypothesis After a femur fracture due to fragility, upon discharge from surgery at the Hospital de la Santa Creu i Sant Pau, including patients in a regional FLS program will make it possible to complete the study of the patient with fracture, improve adherence to treatment of OP (secondary prevention), and obtain better functional recovery.

Interventions

OTHERFracture Territorial Liaison Service afert a Hip fracture

Give a diferent than the current one way of follow up to the patients with hip fracture

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Multicenter clinical trial. Adult patients who consult the Hospital Emergency Department (ED) of the Hospital de la Santa Creu i Sant Pau (HSCSP) for an FxF PSM as a primary or secondary diagnosis will be selected and will be randomized with a 1:1 distribution to be included in the FLS -CTSPau (intervention group) or to receive usual care (control group). The result of the intervention will be evaluated in terms of health outcomes (re-consultations, hospital readmissions and quality of life).

Eligibility

Sex/Gender
ALL
Age
65 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* All hip fractures older than 65 years

Exclusion criteria

* Politraumatic fractures * Metastasic fractures

Design outcomes

Primary

MeasureTime frameDescription
Number of Deaths1 year after discharge% of Number of deaths after 1st year o follow up
Number of Falls1 year after dischargeNumber of Falls 1st year o follow up
Percentage of patients with adequated Osteoporotic treatment1 year after dischargePercentage of patients with adequated osteoporotic treatment

Secondary

MeasureTime frameDescription
Barthel at the end of follow up1 year after dischargeCompare Barthel after hospital discharge with the end of follow up barthel. Minimum is 0 maximum is 100.

Countries

Spain

Contacts

Primary ContactJordi M Marcuello, Doctor
jmartinma@santpau.cat629315207

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026